Core Viewpoint - The "climax needle" concept stock experienced extreme volatility in the market, revealing the dark side of the medical beauty industry and the collusion between capital and human greed [2][3]. Group 1: Medical Device Misrepresentation - The "climax needle" is based on a medical device originally intended for orthopedic use, specifically a PRP preparation device, which was misrepresented in marketing as a vaginal injection for enhancing sexual pleasure [2][4]. - The approval process for PRP devices is stringent, requiring an average of 5.2 years for clinical trials and registration, yet significant regulatory loopholes exist [4]. Group 2: Market Reactions and Financial Implications - The stock of Bawei Co. surged by 2.3 billion yuan on April 26, only to plummet by 9% the next day, indicating a rapid shift from market enthusiasm to panic [3]. - The medical beauty sector's sales of PRP products reached over 1.4 billion yuan in 2023, highlighting the financial scale of the misrepresentation [5]. Group 3: Consumer Impact and Regulatory Response - Numerous cases of severe complications from the "climax needle" have been reported, including infections and permanent damage, underscoring the risks to consumers [7][12]. - Regulatory bodies are taking action, including the launch of a "medical beauty device cleansing action" and the implementation of a black-and-white list system for medical institutions [12]. Group 4: Proposed Solutions - Recommendations for addressing the issues include implementing traceability for medical devices, establishing ethical review committees for medical beauty technologies, and allowing collective lawsuits for consumers [9][10][11].